Media ReleasesSUDA Pharmaceuticals

View All SUDA Pharmaceuticals News

SUDA Pharmaceuticals - R & D Tax Incentive refund received

SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oromucosal drug delivery, is pleased to advise that it has received a refund of $662,009 from the Australian Taxation Office under the R&D Tax Incentive for the 2020 financial year.

The incentive recognises the research and development activities undertaken by SUDA during the last financial year. The receipt of $0.66m in additional funding will further support SUDA’s development work for the current year.

For more information, download the attached PDF.

Download this document